• You are a healthy male or female.
• You are at least 18 and at most 60 years old.
• Your body mass Index (BMI) is at least 18.0 and at most 30.0 kg/m². 
• You do not smoke and you have not used any nicotine-containing products within 2 months prior to the (first) dosing.

Note:

You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to dosing in the research facility (counting from the last dosing in the previous study).

To determine if you are suitable to participate in this trial, you will undergo a medical screening. 

As a female you can only participate if you are not pregnant, not breast feeding and meet one of the following conditions:

• You are using hormonal contraception (for example the contraceptive pill or (copper) intra-uterine device);
• You have passed the menopause (no periods for at least 12 months);
• You have been sterilized or your male partner has been sterilized;
• You are not sexually active according to your lifestyle;
• You are only sexually active with a partner of the same sex.

As a male you can only participate if you meet one of the following conditions:

• You are using a condom in combination with an additional contraception method used by your fertile female partner (for example the contraceptive pill or intra-uterine device);
• You have been sterilized or your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
• You are not sexually active according to your lifestyle;
• You are only sexually active with a partner of the same sex.

Group A11:

The trial consists of 3 periods during each of which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 6 days (5 nights). After these 3 periods there will be 3 short visits, the follow-up visit will take place during the last visit.

Group FE2:

The trial consists of 2 periods during each of which you will stay in the research facility in Groningen (location van Swietenlaan 6) for 5 days (4 nights). After these 2 periods there will be 3 short visits, the follow-up visit will take place during the last visit.

Note: You must be available for all dates to be able to participate in this clinical trial. The current dates of the clinical trial will be published on our website.